Cogstate (ASX: CGS) — Perfil da empresa, notícias e dados financeiros
Cogstate focuses on developing digital cognitive assessment tools for researchers and clinicians globally to assess cognitive function.
Cogstate
Cogstate is a neuroscience and technology company specializing in digital cognitive assessment tools and clinical trial endpoint management services. Headquartered in Melbourne, Australia, the company develops standardized computerized tests and cloud-based software to measure cognitive function in biopharmaceutical clinical trials and clinical care. Cogstate offers solutions including rater training, endpoint data quality monitoring, direct-to-patient remote cognitive evaluations, and scientific consulting. Its platforms support research and drug development across diverse therapeutic indications such as Alzheimer's disease, Parkinson's disease, schizophrenia, major depressive disorder, pediatric rare diseases, and oncology.
Resumo
Operações
Produtos e/ou serviços de Cogstate
- Digital Cognitive Assessment: Standardized computerized cognitive tests administered on digital devices to measure domain-specific brain functions such as memory, attention, and executive function in biopharmaceutical clinical trials and clinical care settings across global research sites.
- Endpoint Data Quality Services: Comprehensive clinician rater training, certification, and audio or video data quality monitoring programs designed to maintain consistent scale administration and reduce scoring variability across international clinical trial study centers.
- Remote Cognitive Assessment: Direct-to-patient decentralized clinical trial solutions and virtual assessment protocols enabling at-home self-administration and remote monitoring of cognitive performance across decentralized biopharmaceutical clinical trials and longitudinal healthcare research studies.
- Healthcare Cognitive Screening: Digital brain health assessment tools and clinical care platforms designed for physicians, healthcare providers, and patients to detect, monitor, and track early cognitive changes in routine clinical settings.
- Scientific Consulting Services: Specialized advisory services providing neuroscientific expertise, clinical trial design, protocol development, cognitive battery selection, and statistical analysis support for pharmaceutical and biotechnology companies developing neuroscience therapeutic candidates.
- Research and Academic Collaborations: Provision of digital cognitive testing platforms, standardized outcome measures, and specialized data management support for investigator-initiated clinical studies, university medical research programs, and non-commercial academic research projects globally.
equipe executiva do Cogstate
- Bradley John O'ConnorCEO, MD & Executive Director
- Darren WatsonCFO & Joint Company Secretary
- Pamela VentolaChief Science Officer
- Rachel ColiteExecutive VP of Clinical Trials
- Paul MaruffFounder & Chief Innovation Officer
- Kenneth BillardChief Commercial Officer
- David James FranksJoint Company Secretary
- Luka LucicSenior Director of Clinical Science in Psychiatry
Comunicados recentes
O que a Cogstate (CGS) comunicou ao mercado, do mais recente para o mais antigo.
- Cogstate 1Q27 Business UpdateFato relevante
- Notification regarding unquoted securities - CGS
- Application for quotation of securities - CGS
Histórico de dividendos
Dividendos por ação pagos pela Cogstate, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026 | — | A$0.0400 | — | A$0.0400 |
| FY2025 | — | A$0.0200 | — | A$0.0200 |
Principais indicadores financeiros
Resultados divulgados pela Cogstate, em USD.
- Cap. de mercado
- 567,9 mi
- Receita (TTM)
- 60,9 mi
- P/L
- 32.9
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- 0.9%
- Margem de lucro
- 19.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 59,9 mi | 12,4 mi | 12,2 mi | |
| 33,3 mi | 7,1 mi | 6,6 mi | |
| 43,4 mi | 2,6 mi | 3,6 mi | |
| 39,9 mi | 2,3 mi | 3,5 mi |